Matsuda, Shinichiro
Suzuki, Ritsuro
Takahashi, Tsutomu
Suehiro, Youko
Tomita, Naoto
Izutsu, Koji
Fukuhara, Noriko
Imaizumi, Yoshitaka
Shimada, Kazuyuki
Nakazato, Tomonori
Yoshida, Isao
Miyazaki, Kana
Yamaguchi, Motoko
Suzumiya, Junji
Funding for this research was provided by:
Japan Agency for Medical Research and Development (JP18ck0106439, J.S.)
Article History
Received: 11 March 2020
Revised: 11 August 2020
Accepted: 25 August 2020
First Online: 3 September 2020
Compliance with ethical standards
:
: Dr. Matsuda has nothing to disclose. Dr. Suzuki reports personal fees from Bristol-Meyer Squib, personal fees from Novartis, personal fees from Kyowa-Hakko Kirin, personal fees from Chugai Pharmaceuticals, personal fees from Shionogi, personal fees from Takeda, personal fees from Meiji Seika Pharma, personal fees from MSD, personal fees from Ohtsuka, personal fees from Sawai, personal fees from Celgene, personal fees from Sumitomo Dainippon, personal fees from Eisai Pharmaceuticals, personal fees from Alexion Pharma, personal fees from Sanofi, personal fees from Gilead Sciences, personal fees from Abbvie, personal fees from Jazz Pharma, personal fees from Ono Pharma, personal fees from Janssen Pharmaceuticals, outside the submitted work; Dr. Takahashi reports personal fees from Kyowa Kirin Co., Ltd., personal fees from CELGENE CORPORATION, personal fees from Bristol-Myers Squibb Company, personal fees from Chugai Pharmaceutical Co., Ltd., outside the submitted work; Dr. Suehiro has nothing to disclose. Dr. Tomita has nothing to disclose. Dr. Izutsu reports grants and personal fees from Gilead Sciences, grants from Eisai, grants and personal fees from MSD, grants and personal fees from Takeda, grants and personal fees from Janssen, personal fees from Bristol Myers Squib, personal fees from Dainihon Sumitomo, grants and personal fees from Mundipharma, personal fees from Nihon Mediphysics, grants and personal fees from Chugai, grants and personal fees from Astrazeneca, grants and personal fees from Bayer, grants and personal fees from Ono, grants from Zenyaku, grants and personal fees from Celgene, grants from Solasia, grants from Symbio, grants from Astellas, grants from Astellas Amgen, grants from Daiichi Sankyo, grants and personal fees from Kyowa Kirin, outside the submitted work; Dr. Fukuhara reports grants and personal fees from Chugai pharma, grants and personal fees from Eisai, grants and personal fees from Kyowa Kirin, grants and personal fees from Janssen, personal fees from Mochida, personal fees from Mundi, personal fees from Nippon Shinyaku, grants and personal fees from Ono Pharmacuetical, grants and personal fees from Takeda, personal fees from Zenyaku, grants and personal fees from Celgene, grants and personal fees from Abbvie, grants from Bayer, grants from Soleisia Pharma, personal fees from Stemline Therapeutics, personal fees from HUYA/IQVIA Services Japan, personal fees from Novartis, grants from Gilead Sciences, outside the submitted work; Dr. Imaizumi has nothing to disclose. Dr. Shimada reports personal fees from AstraZeneca, grants and personal fees from Eisai, grants and personal fees from Celgene, grants from Otsuka Pharmaceutical, grants from MSD, personal fees from Takeda Pharmaceutical, personal fees from Janssen Pharmaceutical, personal fees from Bristol-Myers Squibb, grants and personal fees from Chugai Pharmaceutical, grants and personal fees from Kyowa Kirin, personal fees from Nippon Shinyaku, grants and personal fees from Daiichi Sankyo, outside the submitted work; Dr. Nakazato has nothing to disclose. Dr. Yoshida reports personal fees from Mundi pharma, personal fees from Kyowa Kirin, personal fees from Taiho Pharma, personal fees from Celegene, personal fees from Takeda, personal fees from Bristol Myers Squibb, personal fees from Shire japan, personal fees from Mochida Pharma, personal fees from Chugai Pharma, personal fees from MSD, personal fees from Eisai, personal fees from Janssen, personal fees from Ono Pharma, personal fees from Astrazeneca, during the conduct of the study; Dr. Miyazaki reports grants from Astellas Pharma, grants from Kyowa Kirin, grants from Ono Pharmaceutical, grants from Takeda Pharmaceutical, outside the submitted work; Dr. Yamaguchi reports grants from Astellas Pharma, grants from Kyowa Kirin, grants from Ono Pharmaceutical, grants from Takeda Pharmaceutical, outside the submitted work; Dr. Suzumiya reports grants and personal fees from AstraZeneca, personal fees from Abbvie, grants and personal fees from Eisai, grants and personal fees from Celgene, grants and personal fees from Takeda, grants and personal fees from Chugai, personal fees from Bristrol-Myers Squibb, personal fees from Janssen, grants and personal fees from Symbio, grants from Bayer, grants from Yakult, personal fees from MSD, grants and personal fees from Astellas, grants and personal fees from Elli lli, grants and personal fees from Ohtsuka, grants and personal fees from Ono, grants and personal fees from Kyowa Kirin, personal fees from Shire, personal fees from Zenyaku Kogyo, personal fees from Nippon Shinyaku, grants and personal fees from Sumitomo Dainippon, grants and personal fees from Taiho, personal fees from Novartis, personal fees from Bioverative, personal fees from Pfizer, personal fees from Mochida, grants from Japan Blood Products, grants from Shionogi, grants from Meiji Seika Pharma, personal fees from CSL Behring, outside the submitted work.